ASCO 2023 | A Phase II trial of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma

Stephen Joseph Bagley, MD, MSCE, Hospital of the University of Pennsylvania, Philadelphia, PA, provides an overview of a Phase II (NCT03969706) trial evaluating the efficacy of abemaciclib, a selective CDK4/6 inhibitor, in patients with recurrent oligodendroglioma. The study included patients with IDH-mutant and 1p/19q-codeleted WHO Grade 3 oligodendroglioma who had previously received radiotherapy and alkylating chemotherapy. The primary endpoint was progression-free survival (PFS) status at 6 months. Ten patients were enrolled, and the most common treatment-related adverse event was grade 1-2 diarrhea. Among patients with enhancing tumors, partial response was observed in 2 patients, stable disease in 3 patients, progressive disease in 3 patients, and not evaluable in 1 patient. The median PFSl was 7.7 months. While some patients showed positive responses, the efficacy of abemaciclib in recurrent oligodendroglioma was not sufficient to justify further investigation as a monotherapy. Further studies are needed to identify patients who may benefit from abemaciclib. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.